PBAC's latest decision on Tildrakizumab: Recommended with restriction (2023). Considered for Treatment of severe chronic plaque psoriasis in adult patients enrolled in new clinical trials, via a grandfathering restriction to allow transition from non-PBS-subsidised treatment to PBS-subsidised supply.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
2
first 2018
Submissions
2
2018 → 2023
Eligible population
Adult patients with severe chronic plaque psoriasis (PASI score >15, lesions present ≥6 months) who have received non-PBS-subsidised tildrakizumab treatment prior to listing and demonstrated adequate response (PASI reduction ≥75%).
Therapy area
Dermatology
Line of therapy
Not applicable
Evidence base
Other
Economic model
Not modelled
ICER note
No economic evaluation was conducted for this Category 3 submission, which requested only a grandfathering restriction to an existing PBS listing.
Submission history
Jul 2018: Not recommended · Authority Required
Mar 2023: Recommended with restriction · Authority Required